Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2023.1184
Abstract: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS).To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials.This comparative treatment… read more here.
Keywords: relapsing remitting; disability; effectiveness; fingolimod natalizumab ... See more keywords
Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2018.1489255
Abstract: Abstract Aim: In active relapsing remitting multiple sclerosis (RRMS) patients requiring second-line treatment, the Dutch National Health Care Institute (ZiN) has not stated a preference for either alemtuzumab, fingolimod, or natalizumab. The aim was to… read more here.
Keywords: cost minimization; treatment; minimization analysis; fingolimod natalizumab ... See more keywords
Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/17562864211070449
Abstract: Background: To support innovative trial designs in a regulatory setting for pediatric-onset multiple sclerosis (MS), the study aimed to perform a systematic literature review and meta-analysis of relapse rates with interferon β (IFN β), fingolimod,… read more here.
Keywords: fingolimod natalizumab; analysis; meta analysis; study ... See more keywords